2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

702. CAR-T Cell Therapies: Basic and Translational: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Cell Expansion, Computational Biology, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Gene Therapy, Immunotherapy, Non-Biological Therapies, Radiation Therapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Biological Processes, Genomics, Hematopoiesis, Immune Mechanism, Microbiome, Molecular Biology, Diseases, Immunology, Autoimmune Disorders, Immunodeficiency, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, Translational Research, CML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Study Population, Human, Adult, Elderly, Young Adult, Animal Model
PAPER

5860 Programmable universal fabrack-CAR T cells enable dynamic and concurrent multi-antigen targeting in acute myeloid leukemia (AML)

Cheng-Fu Kuo, PhD, Dandan Zhao, PhD2, Miso Park, PhD3, Guido Marcucci, MD4, John Williams, PhD5, Christine Brown, PhD6, Bin Zhang, PhD7
1 City of Hope Medical Center, Duarte, California, United States
2 City of Hope Medical Center, Duarte, California, United States
3 City of Hope Medical Center, Duarte, California, United States
4 City of Hope Medical Center, Duarte, California, United States
5 City of Hope Medical Center, Duarte, California, United States
6 City of Hope Medical Center, Duarte, California, United States
7 City of Hope Medical Center, Duarte, California, United States

Background: Chimeric antigen receptor (CAR) T-cell therapies targeting tumor-associated antigens have transformed the treatment of several hematologic malignancies. However, their efficacy in AML remains limited by antigen heterogeneity, antigen downregulation, and an immunosuppressive tumor microenvironment, allowing antigen-negative or antigen-low leukemic cells to drive relapse. To overcome these challenges, we developed a universal Fabrack-CAR platform that enables programmable targeting through meditope-engineered antibodies.

Methods: We constructed a universal Fabrack-CAR incorporating an extracellular cyclic 12-amino acid meditope peptide that binds an engineered meditope-binding pocket (meditope-enable) introduced into the Fab arm of monoclonal antibodies (mAbs). Antigen specificity was conferred by administering meditope-enabled mAbs (memAbs) after CAR T-cell infusion, enabling rapid retargeting of a single CAR T-cell product against multiple AML antigens. Antileukemic efficacy was evaluated using in vitro coculture assays and AML Luc⁺ MOLM14 cell-derived xenograft (CDX) and patient-derived xenograft (PDX) models.

Results:We first generated memCD33 antibody adaptors using either the Gemtuzumab or Lintuzumab backbone in an Fc-mutated IgG format for soluble CAR T-cell redirection. Both constructs successfully redirected universal Fabrack-CAR T cells against AML cells and demonstrated potent antileukemic activity in vitro and in vivo. However, the Lintuzumab-derived adaptor significantly prolonged survival in the MOLM14 CDX model compared with the Gemtuzumab-derived adaptor and the no-adaptor control (median survival: 42 vs. 34 vs. 22 days; P=0.0018). Using the Lintuzumab-derived adaptor, we subsequently developed a monovalent Fab adaptor that retained antileukemic efficacy comparable to the IgG format while offering greater translational potential.

Because the memCD33-targeting Fab adaptor showed dose-dependent AML killing in vitro, we evaluated three doses (3, 10, or 30 μg/mouse) and two dosing schedules (3 or 5 doses per week) in Luc⁺ MOLM14 CDX models. All regimens demonstrated comparable efficacy, indicating dosing flexibility. We next engineered a memCD123-targeting Fab adaptor, which exhibited dose-dependent antileukemic activity comparable to the memCD33 adaptor but required a higher dose to achieve similar efficacy (30 vs. 10 μg/mouse).

To overcome antigen heterogeneity, we engineered a bispecific memFab adaptor targeting both CD33 and CD123. Universal Fabrack-CAR T cells redirected by the dual-targeting adaptor exhibited robust cytokine production and efficient killing of MOLM14 cells in vitro. To monitor leukemia and CAR T cells in vivo, we generated AccaLuc+ MOLM14 and Luc⁺ Fabrack-CAR T cells, to simultaneously monitor leukemic burden and CAR T-cell infiltration and persistence in vivo. In NSG mice bearing AccaLuc+ MOLM14 AML, Fabrack-CAR T cells were infused on day 3, followed by single- or dual-targeting adaptors. The dual-targeting adaptor administered at doses of 3 or 10  μg/mouse significantly reduced leukemia burden and prolonged survival compared with either single-targeting adaptor (dual-targeting vs. anti-CD33: 83 vs. 47 days, P=0.0018; dual-targeting vs. anti-CD123: 83 vs. 34 days, P=0.0018). All mice treated with the dual-targeting adaptor remained leukemia-free for >90 days. Leukemia burden inversely correlated with CAR T-cell persistence.

The superior efficacy of the dual-targeting adaptor (10 μg/mouse) was further confirmed in AML PDX models, where it significantly reduced leukemia burden and prolonged survival compared with the no-adaptor control group (median survival: 52 vs. 26 days; P = 0.0018). Importantly, BM cells from dual-targeting adaptor-treated mice failed to transmit leukemia upon secondary transplantation; no recipient developed AML and median survival was not reached, whereas all recipients of control BM succumbed within 28 days, demonstrating functional eradication of leukemia-propagating cells.

Conclusions: The universal Fabrack-CAR platform enables programmable, interchangeable redirection of a single CAR T-cell product against multiple AML antigens. Dual-targeting adaptors demonstrated superior antileukemic efficacy over single-antigen targeting and eliminated leukemia-propagating cells, highlighting the potential of programmable multi-antigen targeting to overcome antigen heterogeneity and immune escape in AML and supporting future clinical translation.

Cheng-Fu Kuo, PhD: No relevant conflicts of interest to declare.